![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MedMira Inc | TSXV:MIR | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.08 | 0.075 | 0.085 | 0 | 12:00:28 |
HALIFAX, Dec. 28, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, reported today on its financial results for the three month period ending October 31, 2012. The Company's revenues were up by $309,728 over the same quarter last year.
"Adding to our top line growth in the first quarter was revenue recognized as a result of our ongoing product development and commercialization contract with the US Army," said Daniel Frid, CFO, MedMira Inc. "The first quarter also brought the conclusion of our debt restructuring initiative, including re-negotiated debt holder arrangements, decreased interest rates, and more favorable payment terms through this fiscal year. This initiative strengthened the Company's operating base and now allows it to focus on strategic business development and product commercialization initiatives."
Frid added, "Working together with strategic partners, our sales, marketing and business development activities are advancing well in a number of key areas including the military sector, technology platform development, and sales in international markets, such as Latin America where we saw an increase this quarter with a strong and growing interest in the Multiplo line."
First Quarter Financial Highlights
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
Copyright 2012 Canada NewsWire
1 Year MedMira Chart |
1 Month MedMira Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions